A hallmark of Alzheimer's disease (AD) is the presence of beta-Amyloid in plaques in the brains of patients. N-terminally truncated pyroglutamate-modified beta-Amyloid forms such as Aß(3-40) and Aß (11- 40) have been described as major compounds in the senile plaques. Pyro-Glu modified beta-Amyloid forms are more resistant to degradation, show higher toxicity and have increased aggregation propensity compared to non-modified beta-Amyloid. (Shipping Cost: €35.00)

[Pyr3]-beta-Amyloid (3-40)

A hallmark of Alzheimer's disease (AD) is the presence of beta-Amyloid in plaques in the brains of patients. N-terminally truncated pyroglutamate-modified beta-Amyloid forms such as Aß(3-40) and Aß (11- 40) have been described as major compounds in the se